World Diabetes Day 2024 – Meet EIC beneficiary BOYDSense: pioneering non-invasive diabetes monitoring solutions

As every year since 1991, on 14 November, World Diabetes Day is commemorated, with this year’s theme – ‘Diabetes and Wellbeing’ – highlighting the importance of appropriate access to diabetes care and support for patients’ well-being. 
For this reason, on this global recurrence, we are spotlighting the EIC Accelerator Blended Finance project, Lassie, whose recent financial achievements will enable further steps toward the market launch of its groundbreaking breath-based glucose monitoring solution. 

Requiring the download of a smartphone app and simple breathing into the device for blood glucose value calculations, the French company’s solution promises easier and more accessible diabetes management for all those living with diabetes and pre-diabetes. 

Addressing today’s key challenges in glucose monitoring  

Award-winning startup with R&D in France and the United States, since its founding in 2015, BOYDSense has been committed to advancing non-invasive health monitoring and diagnosis solutions to tackle three major challenges of blood glucose monitoring (BGM), still roughly used by 100 million people worldwide: 

• Its invasive nature, requiring plenty of supply through test strips and lancets 
• Its high cost, still inaccessible to a large majority 
• Its impact on the environment due to the production of consumables 

Ben Delhey, Chief Executive Officer (CEO) at BOYDSense, highlights: 

Our solution is pain-free, affordable, and only one consumable is needed, which leads to produce significantly less waste compared to existing fingerstick blood glucose or continuous glucose monitors and reduces the hassle for people with Diabetes to manage the supply.

A step closer towards market launch of its innovation 

Following the conclusion in 2023 of the latest clinical study – conducted in partnership with Toulouse University Hospital – confirming the potential of BOYDSense’s innovative breath glucose measurement platform, the medical technology company recently announced the completion of a 7 million euros capital increase with the closing of a new financing round led by the Swiss Diabetes Venture Fund, Bioserenity and the European Innovation Council Fund.  

Commenting on the medical technology company’s recent financial achievement, its CEO, Ben Delhey referred: 

Since the financing earlier this year, we have made significant progress in the device development, such as further miniaturization of the device, design work, and improved Bill of materials. Additionally, we have initiated new clinical trials to improve our algorithm and are working to become ISO 13485 certified. We are currently in good discussions with regulatory bodies in US and Europe.

© BOYDSense Official Website

Accelerating the world’s transition to non-invasive health monitoring amidst clinical challenges 

As BOYDSense’s CEO, Ben Delhey, specifies, despite difficulties in generating enough clinical trial data in the path towards the advancement of the breath-based monitoring technology, the European Innovation Council grant – through which the Lassie project is funded – significantly helped BOYDSense in this regard. 

Indeed, the grant helped BOYDSense create more clinical evidence – facilitating progress in the development of the innovative device – and it helped attract new investors, namely the Swiss Diabetes Venture Fund, Bioserenity and the European Innovation Council Fund. 

Additional information   

BOYDSense became an EIC Accelerator Blended Finance beneficiary with the Lassie project, which benefits from the company’s know-how and pioneering role in the development of non-invasive breath analysis solutions for the risk stratification, detection and monitoring of biomarkers.  

For more information on the Lassie project and its transformative impact on helping empower patients affected by diabetes and pre-diabetes conditions, please visit the dedicated page on CORDIS.